{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:39:11Z","timestamp":1761863951908,"version":"3.37.3"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"31","license":[{"start":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T00:00:00Z","timestamp":1557532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Swedish government"},{"DOI":"10.13039\/501100009240","name":"Swedish Association of Local Authorities and Regions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009240","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Randomized clinical trials have consistently demonstrated the non-inferiority of bioabsorbable polymer drug-eluting stents (BP-DES) with respect to DES having permanent polymers (PP-DES). To date, the comparative performance of BP- and PP-DES in the real world has not been extensively investigated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>From October 2011 to June 2016, we analysed the outcomes associated with newer generation DES use in Sweden. After stratification according to the type of DES received at the index procedure, a total of 16\u00a0504 and 79\u00a0106 stents were included in the BP- and PP-DES groups, respectively. The Kaplan\u2013Meier estimates for restenosis at 2\u2009years were 1.2% and 1.4% in BP- and PP-DES groups, respectively. Definite stent thrombosis (ST) was low in both groups (0.5% and 0.7% in BP- and PP-DES groups, respectively). The adjusted hazard ratio (HR) for either restenosis or definite ST did not differ between BP- and PP-DES [adjusted HR 0.95, 95% confidence interval (CI) 0.74\u20131.21; P\u2009=\u20090.670 and adjusted HR 0.79, 95% CI 0.57\u20131.09; P\u2009=\u20090.151, respectively]. Similarly, there were no differences in the adjusted risk of all-cause death and myocardial infarction (MI) between the two groups (adjusted HR for all-cause death 1.01, 95% CI 0.82\u20131.25; P\u2009=\u20090.918 and adjusted HR for MI 1.05, 95% CI 0.93\u20131.19; P\u2009=\u20090.404).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In a large, nationwide, and unselected cohort of patients, percutaneous coronary intervention with BP-DES implantation was not associated with an incremental clinical benefit over PP-DES use at 2 years follow-up.<\/jats:p>\n                  <jats:p\/>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehz244","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T11:44:44Z","timestamp":1554464684000},"page":"2607-2615","source":"Crossref","is-referenced-by-count":20,"title":["Clinical and angiographic outcomes of bioabsorbable vs. permanent polymer drug-eluting stents in Sweden: a report from the Swedish Coronary and Angioplasty Registry (SCAAR)"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7767-3073","authenticated-orcid":false,"given":"Sergio","family":"Buccheri","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Dag Hammarskj\u00f6lds V\u00e4g 38, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"James","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Dag Hammarskj\u00f6lds V\u00e4g 38, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Lindholm","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Dag Hammarskj\u00f6lds V\u00e4g 38, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole","family":"Fr\u00f6bert","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Health, \u00d6rebro University, S\u00f6dra Grev Rosengatan, \u00d6rebro, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00f6ran K","family":"Olivecrona","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Persson","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Danderyd University Hospital, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Hambraeus","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Falu Lasarett, Falun, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Witt","sequence":"additional","affiliation":[{"name":"Unit of Cardiology, Department of Clinical Science and Education, Karolinska Institutet, S\u00f6dersjukhuset, Sjukhusbacken 10, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Erlinge","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oskar","family":"Anger\u00e5s","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sahlgrenska University Hospital, Bruna str\u00e5ket 16, G\u00f6teborg, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Lagerqvist","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Dag Hammarskj\u00f6lds V\u00e4g 38, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Sarno","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Dag Hammarskj\u00f6lds V\u00e4g 38, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,5,11]]},"reference":[{"key":"2022102609153487600_ehz244-B1","doi-asserted-by":"crossref","first-page":"706","DOI":"10.4244\/EIJ-D-17-00557","article-title":"State of the art: coronary artery stents\u2014past, present and future","volume":"13","author":"Stefanini","year":"2017","journal-title":"EuroIntervention"},{"key":"2022102609153487600_ehz244-B2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102609153487600_ehz244-B3","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehu213","article-title":"Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial","volume":"35","author":"Head","year":"2014","journal-title":"Eur Heart J"},{"key":"2022102609153487600_ehz244-B4","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(17)31927-X","article-title":"Coronary balloon angioplasty, stents, and scaffolds","volume":"390","author":"Byrne","year":"2017","journal-title":"Lancet"},{"key":"2022102609153487600_ehz244-B5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.107.730010","article-title":"Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries","volume":"120","author":"Wilson","year":"2009","journal-title":"Circulation"},{"key":"2022102609153487600_ehz244-B6","first-page":"139","article-title":"Current state of bioabsorbable polymer-coated drug-eluting stents","volume":"13","author":"Akinapelli","year":"2017","journal-title":"Curr Cardiol Rev"},{"key":"2022102609153487600_ehz244-B7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00019501-200409000-00003","article-title":"Drug-eluting stents: caution and concerns for long-term outcome","volume":"15","author":"Virmani","year":"2004","journal-title":"Coron Artery Dis"},{"key":"2022102609153487600_ehz244-B8","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jacc.2011.12.016","article-title":"Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent","volume":"59","author":"Meredith","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2022102609153487600_ehz244-B9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)61852-2","article-title":"Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial","volume":"381","author":"Smits","year":"2013","journal-title":"Lancet"},{"key":"2022102609153487600_ehz244-B10","doi-asserted-by":"crossref","first-page":"e001441","DOI":"10.1161\/CIRCINTERVENTIONS.114.001441","article-title":"Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial","volume":"8","author":"Windecker","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"2022102609153487600_ehz244-B11","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/eurheartj\/ehu210","article-title":"A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial","volume":"35","author":"Saito","year":"2014","journal-title":"Eur Heart J"},{"key":"2022102609153487600_ehz244-B12","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/eurheartj\/ehr479","article-title":"Lower risk of stent thrombosis and restenosis with unrestricted use of \u2018new-generation\u2019 drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR)","volume":"33","author":"Sarno","year":"2012","journal-title":"Eur Heart J"},{"key":"2022102609153487600_ehz244-B13","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"2022102609153487600_ehz244-B14","doi-asserted-by":"crossref","first-page":"f6625.","DOI":"10.1136\/bmj.f6625","article-title":"Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis","volume":"347","author":"Bangalore","year":"2013","journal-title":"BMJ"},{"key":"2022102609153487600_ehz244-B15","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jcin.2016.12.002","article-title":"Meta-analysis of randomized clinical trials comparing biodegradable polymer drug-eluting stent to second-generation durable polymer drug-eluting stents","volume":"10","author":"El-Hayek","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"2022102609153487600_ehz244-B16","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.4244\/EIJ-D-17-00529","article-title":"Final five-year clinical outcomes in the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent","volume":"17","author":"Meredith","year":"2018","journal-title":"EuroIntervention"},{"key":"2022102609153487600_ehz244-B17","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1093\/eurheartj\/ehy273","article-title":"Temporal course of vascular healing and neoatherosclerosis after implantation of durable- or biodegradable-polymer drug-eluting stents","volume":"39","author":"Guagliumi","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102609153487600_ehz244-B18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/ehjqcco\/qcy036","article-title":"A meta-analysis of randomized controlled trials to compare long-term clinical outcomes of bioabsorbable polymer and durable polymer drug-eluting stents","volume":"5","author":"Mridha","year":"2019","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2022102609153487600_ehz244-B19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1161\/CIRCULATIONAHA.118.038065","article-title":"ISAR-TEST 4 (Intracoronary Stenting and Angiographic Results: test Efficacy of 3 Limus-Eluting Stents) Investigators. Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease: results From the ISAR-TEST 4 Randomized Trial","volume":"139","author":"Kufner","year":"2019","journal-title":"Circulation"},{"key":"2022102609153487600_ehz244-B20","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1016\/j.jacc.2018.09.019","article-title":"Ultrathin bioresorbable polymer sirolimus-eluting stents versus thin durable polymer everolimus-eluting stents","volume":"72","author":"Kandzari","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102609153487600_ehz244-B21","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1161\/CIRCULATIONAHA.118.034456","article-title":"Newer-generation ultrathin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease","volume":"138","author":"Bangalore","year":"2018","journal-title":"Circulation"},{"key":"2022102609153487600_ehz244-B22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/40\/31\/2607\/46639287\/eurheartj_40_31_2607.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/40\/31\/2607\/46639287\/eurheartj_40_31_2607.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T09:16:09Z","timestamp":1666775769000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/40\/31\/2607\/5488150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,11]]},"references-count":22,"journal-issue":{"issue":"31","published-online":{"date-parts":[[2019,5,11]]},"published-print":{"date-parts":[[2019,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehz244","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"type":"print","value":"0195-668X"},{"type":"electronic","value":"1522-9645"}],"subject":[],"published-other":{"date-parts":[[2019,8,14]]},"published":{"date-parts":[[2019,5,11]]}}}